| Bioactivity | Dubermatinib (TP-0903) is a potent and selective Axl receptor tyrosine kinase inhibitor with an IC50 value of 27 nM. | ||||||||||||
| Invitro | Dubermatinib (TP-0903) displays a potent activity against AXL with an IC50 of 0.027 μM. Dubermatinib (TP-0903) shows extremely potent activity in cell viability assays with an IC50 of 6 nM against the pancreatic cancer cell line PSN-1. Dubermatinib (TP-0903) is evaluated for its ability to block GAS6-mediated activation of AXL in pancreatic cancer cells. PSN-1 cells are serum-starved and then stimulated with GAS6 in the presence of various concentrations of TP-0903[1]. | ||||||||||||
| Name | Dubermatinib | ||||||||||||
| CAS | 1341200-45-0 | ||||||||||||
| Formula | C24H30ClN7O2S | ||||||||||||
| Molar Mass | 516.06 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Dubermatinib
CAS: 1341200-45-0 F: C24H30ClN7O2S W: 516.06
Dubermatinib (TP-0903) is a potent and selective Axl receptor tyrosine kinase inhibitor with an IC50 value of 27 nM.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.